<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02188082</url>
  </required_header>
  <id_info>
    <org_study_id>LSQYFBLDHF2013</org_study_id>
    <nct_id>NCT02188082</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）</brief_title>
  <acronym>FIRST</acronym>
  <official_title>Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ivabradine acts by inhibiting the ionic If current that modulates the pacemaker activity of&#xD;
      sinoatrial node cells. The aim of present study is to evaluate the efficacy and safety of&#xD;
      IvabRadine hemisulfate Sustained-release Tablets versus placebo in patients with moderate to&#xD;
      severe chronic systolic heart failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Left Ventricular End Systolic Volume Index by ultrasound cardiogram</measure>
    <time_frame>baseline and week 32</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Left Ventricular End Diastolic Volume Index and left ventricular ejection fraction(LVEF)</measure>
    <time_frame>baseline and week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of hospital admission for worsening heart failure、any cardiovascular hospital admission、 cardiovascular mortality、all-cause mortality</measure>
    <time_frame>baseline and week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in distance of 6-minute walking test</measure>
    <time_frame>baseline and week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in heart rate</measure>
    <time_frame>baseline and week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in scores of Kansas City Cardiomyopathy Questionnaire</measure>
    <time_frame>baseline and week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in NT-proBNP</measure>
    <time_frame>baseline and week 32</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Chronic Systolic Heart Failure</condition>
  <arm_group>
    <arm_group_label>IvabRadine hemisulfate Sustained-release Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-15mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5-15mg qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IvabRadine hemisulfate Sustained-release Tablets</intervention_name>
    <arm_group_label>IvabRadine hemisulfate Sustained-release Tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged from 18 to 75 years, males or females&#xD;
&#xD;
          -  Willing to provide written informed consent&#xD;
&#xD;
          -  NYHA Class II, III, or IV for≥4 weeks, in stable clinical condition for&#xD;
&#xD;
             ≥4 weeks&#xD;
&#xD;
          -  Optimized and unchanged chronic heart failure medications and dosages for≥4 weeks&#xD;
&#xD;
          -  Sinus rhythm with resting heart rate≥70 b.p.m.&#xD;
&#xD;
          -  Left-ventricular systolic dysfunction, with ejection fraction≥40% documented within&#xD;
             previous 1 month&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable cardiovascular condition(for example, hospital admission for worsening heart&#xD;
             failure)&#xD;
&#xD;
          -  Recent (&lt;2 months) myocardial infarction or recent or scheduled coronary&#xD;
             revascularization&#xD;
&#xD;
          -  Stroke or transient cerebral ischaemia within previous 4 weeks&#xD;
&#xD;
          -  Severe primary valvular disease&#xD;
&#xD;
          -  Scheduled surgery of valvular heart disease&#xD;
&#xD;
          -  Active myocarditis&#xD;
&#xD;
          -  Congenital heart diseases&#xD;
&#xD;
          -  peripartum cardiomyopathy&#xD;
&#xD;
          -  hyperthyroid heart disease&#xD;
&#xD;
          -  On list for cardiac transplantation&#xD;
&#xD;
          -  Cardiac resynchronization therapy started within previous 6 months&#xD;
&#xD;
          -  Pacemaker with atrial or ventricular pacing (except biventricular pacing)˃40% of the&#xD;
             time, or with stimulation threshold at the atrial or ventricular level˃60 b.p.m.&#xD;
&#xD;
          -  Permanent atrial fibrillation or flutter&#xD;
&#xD;
          -  Sick sinus syndrome, sinoatrial block, second and third degree atrio-ventricular block&#xD;
&#xD;
          -  History of symptomatic or sustained (≥30 s) ventricular arrhythmia unless a&#xD;
             cardioverter/defibrillator implanted&#xD;
&#xD;
          -  Cardioverter/defibrillator shock within previous 6 months&#xD;
&#xD;
          -  Family history or congenital long QT syndrome or treated with selected QT-prolonging&#xD;
             products(except amiodarone)&#xD;
&#xD;
          -  Contraindication or intolerance to ivabradine or lactulose&#xD;
&#xD;
          -  Severe or uncontrolled hypertension (SBP≥180 mmHg or DBP≥110 mmHg)&#xD;
&#xD;
          -  known anaemia(Hb&lt;100 g/L)&#xD;
&#xD;
          -  Known moderate or severe liver disease(ALT/AST˃3ULN), known severe renal&#xD;
             disease(Cr˃2ULN)&#xD;
&#xD;
          -  Pregnant or lactating women and women planning to become pregnant&#xD;
&#xD;
          -  Use of an investigational drug within 30 days of enrollment&#xD;
&#xD;
          -  Has a history of psychological illness/condition that interferes with ability to&#xD;
             understand or complete requirements of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianan Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianan Wang, doctor</last_name>
    <phone>0571-87315001</phone>
    <email>wang_jian_an@tom.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The military general hospitla of Beijing PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junxia Li</last_name>
    </contact>
    <investigator>
      <last_name>Junxia Li</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The second affiliated hospital of suzhou university</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yang Jiao</last_name>
    </contact>
    <investigator>
      <last_name>Yang Jiao</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Subei People's Hospital of Jiangsu province</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiang Gu</last_name>
    </contact>
    <investigator>
      <last_name>Xiang Gu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>the First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yu Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Yu Zhang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>shengjing hospital of China medical university</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shumei Ma</last_name>
    </contact>
    <investigator>
      <last_name>Shumei Ma</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ming Zhong</last_name>
    </contact>
    <investigator>
      <last_name>Ming Zhong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>the Second Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qinghua Lu</last_name>
    </contact>
    <investigator>
      <last_name>Qinghu Lu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of zhejiang university school of medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaosheng Hu</last_name>
    </contact>
    <investigator>
      <last_name>Xiaosheng Hu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hangzhou First People'S Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yizhou Xu</last_name>
    </contact>
    <investigator>
      <last_name>Yizhou Xu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The second affiliated hospital of zhejiang university school of medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianan Wang, doctor</last_name>
    </contact>
    <investigator>
      <last_name>Jianan Wang, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of wenzhou medical university</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weijian Huang</last_name>
    </contact>
    <investigator>
      <last_name>Weijian Huang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The second affiliated hospital of wenzhou medical university</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jifei Tang</last_name>
    </contact>
    <investigator>
      <last_name>Jifei Tang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>July 9, 2014</study_first_submitted>
  <study_first_submitted_qc>July 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2014</study_first_posted>
  <last_update_submitted>July 10, 2014</last_update_submitted>
  <last_update_submitted_qc>July 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
    <mesh_term>Systolic Murmurs</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

